LONA
LeonaBio Inc. · NASDAQ
- Market cap
- $36.1M
LeonaBio Inc. (LONA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for LONA, including 2 insider trades, 2 13D/G filings and 1 press release or news item. The most recent was published Nov 16, 2026.
Financial highlights
Full financials- Net income, TTM
- -$156.01M
- Cash
- $16.34M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks29+100%
2026-05-242026-11-15
Mix1290d
- Other3(25%)
- SEC Filings3(25%)
- Insider3(25%)
- 13D/G2(17%)
- Earnings1(8%)
Activity · 52 weeks8337 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECLeonaBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LeonaBio, Inc. (LONA) (CIK 0001620463)
- PRLeonaBio Reports Third Quarter 2026 Financial Results and Provides Business UpdateBOTHELL, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended September 30, 2026, and provided recent pipeline and business updates. "We continue to execute with focus and discipline as we advance ELAINE-3 and target completion of enrollment in the fourth quarter of 2026," said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. "With enrollment nearing completion, we are entering a pivotal phase in the development of lasofoxifene. Our efforts extend beyond clini
- 13D/GSEC Form SCHEDULE 13G filed by LeonaBio Inc.SCHEDULE 13G - LeonaBio, Inc. (0001620463) (Subject)
- 13D/GSEC Form SCHEDULE 13G filed by LeonaBio Inc.SCHEDULE 13G - LeonaBio, Inc. (0001620463) (Subject)
- INSIDERLarge owner Portman David J. bought $9,919,161,281 worth of shares (3,149,470 units at $3,149.47) (SEC Form 4)4 - LeonaBio, Inc. (0001620463) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.SCHEDULE 13D/A - LeonaBio, Inc. (0001620463) (Subject)
- INSIDERSEC Form 4 filed by LeonaBio Inc.4 - LeonaBio, Inc. (0001620463) (Issuer)
- SECLeonaBio Inc. filed SEC Form 8-K: Other Events8-K - LeonaBio, Inc. (0001620463) (Filer)
- INSIDERSEC Form 3 filed by new insider Portman David J.3 - LeonaBio, Inc. (0001620463) (Issuer)
- PRLeonaBio to Participate in Cantor Global Healthcare Conference 2026BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Company management will participate in the Cantor Global Healthcare Conference 2026, taking place September 9-11, 2026 in New York, NY. Details are as follows: Cantor Global Healthcare Conference 2026Format: Fireside ChatDate and Time: Friday, September 11, 2026, from 9:45 am – 10:15 am EDTLocation: New York, NY A live webcast of the fireside chat can be accessed from the Investors section of the LeonaBio website at https://investors.leonabio.com/news-
- SECLeonaBio Inc. filed SEC Form 8-K: Other Events8-K - LeonaBio, Inc. (0001620463) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.SCHEDULE 13D/A - LeonaBio, Inc. (0001620463) (Subject)
- PRLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateOn Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, Wash., Aug. 14, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended June 30, 2026, and provided recent pipeline and business updates. "We enter the second half of 2026 with a clear focus on executing our Phase 3 ELAINE-3 trial and advancing lasofoxifene toward what we believe could b
- ANALYSTLeonaBio upgraded by Citizens with a new price targetCitizens upgraded LeonaBio from Mkt Perform to Mkt Outperform and set a new price target of $18.00
- INSIDERSEC Form 4 filed by Director Perceptive Advisors Llc4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Perceptive Advisors Llc4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Callori Fred4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Holles Natalie C.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Silverman Peter B.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Panzara Michael A.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Romano Kelly A4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Edelman Joseph4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson James A4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Kosacz Barbara4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Pickering Grant4 - LeonaBio, Inc. (0001620463) (Issuer)
LONA FAQ
9 questionsWhat is the latest news on LONA?
In the last 30 days Quantisnow tracked 7 wire items for LONA: 2 insider trades, 2 13D/G filings, 1 press release or news item and 1 earnings update. The most recent was published on November 16, 2026.Is LONA profitable?
No. LeonaBio Inc. reported a net loss of $156.01M for the twelve months ended Sep 30, 2026.How much cash and debt does LONA have?
LeonaBio Inc. reported $16.34M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does LONA stock trade?
LeonaBio Inc. (LONA) is listed on NASDAQ.What sector and industry is LONA in?
LeonaBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did LeonaBio Inc. go public?
LeonaBio Inc. (LONA) completed its IPO in 2020.What are analysts saying about LONA?
Across the last 4 analyst actions on LeonaBio Inc., there were 2 upgrades and 0 downgrades. The most recent action was from Citizens: Mkt Outperform with a $18.00 price target on 2026-07-30. Recent price targets range from $10.00 to $20.00.What companies are similar to LONA?
Notable peers in the same industry include BIIB (Biogen Inc.), AMGN (Amgen Inc.), ALNY (Alnylam Pharmaceuticals Inc.), SRPT (Sarepta Therapeutics Inc.), VRTX (Vertex Pharmaceuticals Incorporated). Compare LONA side-by-side with any of them on Quantisnow.How can I track LONA on Quantisnow?
Quantisnow aggregates LeonaBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LONA to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change